Latest / This Week In Medicine
NEJM: Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
This clinical study investigates whether combining the targeted drug osimertinib with traditional chemotherapy offers a superior outcome for patients facing a specific type of advanced lung cancer. By comparing this dual approach against the standard single-drug therapy, researchers discovered that the combination treatment significantly extended the livesof participants by nearly ten months. While the combined regimen proved more effective at keeping the disease at bay, it also resulted in a higher frequency of severe side effects compared to the solo medication. Ultimately, the trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.